Nabilone and other antiemetics for cancer patients.
D000932:Antiemetics / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002090:Butyrophenones / Q000627:therapeutic use; D013759:Dronabinol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008787:Metoclopramide / Q000627:therapeutic use; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D010640:Phenothiazines / Q000627:therapeutic use
D000932:Antiemetics; D000970:Antineoplastic Agents; D002090:Butyrophenones; D005938:Glucocorticoids; D010640:Phenothiazines; C011941:nabilone; D013759:Dronabinol; D008787:Metoclopramide